FEMY Femasys Forecast, Technical & Fundamental Analysis
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas... Show more
FEMY is expected to report earnings to fall 24.81% to -100 cents per share on November 17
Q3'26
Est.
$-1.00
Q2'26
Missed
by $0.20
Q1'26
Beat
by $1.80
Q4'25
Beat
by $0.03
Q3'25
Beat
by $0.03
The last earnings report on August 17 showed earnings per share of -133 cents, missing the estimate of -112 cents. With 30.64K shares outstanding, the current market capitalization sits at 24.08M.
A.I.dvisor tells us that FEMY and OFIX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FEMY and OFIX's prices will move in lockstep.
FEMY's RSI Indicator ascends from oversold territory
The RSI Oscillator for FEMY moved out of oversold territory on August 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In of the 37 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 76 cases where FEMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 21, 2026. You may want to consider a long position or call options on FEMY as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for FEMY just turned positive on August 19, 2026. Looking at past instances where FEMY's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FEMY advanced for three days, in of 186 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FEMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for FEMY entered a downward trend on August 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.974) is normal, around the industry mean (5.068). P/E Ratio (0.000) is within average values for comparable stocks, (146.194). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.298). Dividend Yield (0.000) settles around the average of (0.017) among similar stocks. P/S Ratio (3.719) is also within normal values, averaging (75.119).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. FEMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FEMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
